Cardinal 3PL Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Cardinal 3PL Pharmaceutical Import Records from India — 2 Products, $2.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cardinal 3PL — Pharmaceutical Importer Profile (2026) | 2 Products, $2.5M Trade | TransData Nexus

Cardinal 3PL

Pharmaceutical Importer · United States · Antihistamines & Allergy Focus · $2.5M Total Trade · DGFT Verified

Cardinal 3PL is a pharmaceutical importer based in United States with a total trade value of $2.5M across 2 products in 2 therapeutic categories. Based on 51 verified import shipments from Indian Customs (DGFT) records, Cardinal 3PL is the #1 buyer in 1 product including Diphenhydramine. Cardinal 3PL sources from 3 verified Indian suppliers, with Micro Labs Limited accounting for 68.9% of imports.

Cardinal 3PL — Import Portfolio & Supplier Network

Cardinal 3PL import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cardinal 3PL?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$5.1M	120	68.9%
Caplin Steriles Limited	$2.2M	51	29.8%
Brooks Steriscience Limited	$100.0K	2

What Formulations Does Cardinal 3PL Import?

Formulation	Value	Ships
Diphenhydramine hcl injection USP	$250.0K	5
Levetiracetam injection, USP 500MG/5ML	$182.1K	4
Verapamil hydrochloride injection USP	$157.7K	4
Diphenhydramine hcl injection USP	$150.0K	3
Diphenhydramine hcl injection USP 50MG/ML ( 25x1ml ) ( qty- 25294.000	$150.0K	3
Diphenhydramine hydrochloride injectionusp 50MG/ML (25x1ml) - tax invoice no: 714201047 dt	$150.0K	3
Thiamine hydrochloride injection USP 200MG/2ML (100MG/ML) - 2ML	$150.0K	3
Tranexamic acid injection 100MG/ML in 10ML	$150.0K	3
Tranexamic acid injection solution USP	$144.8K	3
Thiamine hydrochloride injection USP	$144.7K	3
Diphenhydramine hcl injection USP 50MG/ML (5x1ml) - tax invoice no: 714201041 dt	$142.9K	3
Thiamine hydrochloride injection USP 200MG/2ML (100MG/ML)2mlbatch	$142.3K	4
Sodium nitroprusside injection 50MG/2ML(25MG/ML) (1x2ml) - tax invoice no: 714201057 dt	$121.2K	3
Thiamine hydrochloride injection USP,200MG/2ML (100MG/ML)2ML,batch	$112.6K	3
Levetiracetam injection, USP	$100.0K	2

Cardinal 3PL imports 130 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diphenhydramine	Antihistamines & Allergy	$1.9M	38	5.9%	1
2	Verapamil	Cardiovascular	$650.0K	13	0.6%	8

Cardinal 3PL imports 2 pharmaceutical products across 2 categories into United States totaling $2.5M. The company is the #1 buyer for 1 product: Diphenhydramine.

Cardinal 3PL — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cardinal 3PL is a United States-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from international suppliers, particularly from India. Operating as a third-party logistics (3PL) provider, Cardinal 3PL plays a pivotal role in the U.S. pharmaceutical distribution network by sourcing and importing a diverse range of pharmaceutical products to meet domestic demand. The company is headquartered at 501 Mason Rd, Suite 200, LaVergne, Tennessee, 37086.

In the fiscal years 2022 to 2026, Cardinal 3PL has demonstrated a consistent and strategic approach to pharmaceutical procurement. The company has imported a total of $2.5 million USD worth of finished pharmaceutical formulations from India, encompassing 51 shipments. These imports span two therapeutic categories, with a portfolio concentration where the top five products account for 100% of the total import value. This indicates a highly focused sourcing strategy, emphasizing specific products to meet targeted market needs.

2Distribution Network

Cardinal 3PL's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the United States. The company's primary warehouse is located at 501 Mason Rd, Suite 200, LaVergne, Tennessee, serving as a central hub for receiving, storing, and distributing imported pharmaceutical formulations. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the centralization of operations in Tennessee suggests a focus on optimizing supply chain efficiency and reducing lead times for nationwide distribution.

3Industry Role

Within the U.S. pharmaceutical supply chain, Cardinal 3PL functions as a specialized importer and distributor of finished pharmaceutical formulations. By sourcing products from international manufacturers, particularly from India, the company supplements domestic production and ensures a steady supply of essential medications. This role is crucial in maintaining the diversity and availability of pharmaceutical products in the U.S. market, catering to various therapeutic needs and patient populations.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cardinal 3PL

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cardinal 3PL's sourcing strategy exhibits a high degree of concentration, with the top five products imported accounting for 100% of the total import value. This indicates a deliberate focus on specific products, potentially to leverage volume discounts, streamline inventory management, and establish strong supplier relationships. However, such concentration also introduces risks, including supply chain disruptions if any of the key suppliers face operational challenges. The company's reliance on a limited number of suppliers, notably MICRO LABS LIMITED and CAPLIN STERILES LIMITED, suggests a strategic choice to maintain consistency and quality in its product offerings. The stability of these supplier relationships is critical to Cardinal 3PL's operational success, and any significant changes in supplier performance could impact the company's ability to meet market demand.

2Supply Chain Resilience

Cardinal 3PL's supply chain resilience is closely tied to the reliability of its key Indian suppliers. The company's imports are predominantly sourced from MICRO LABS LIMITED and CAPLIN STERILES LIMITED, which together account for the majority of the import value. This concentrated supplier base may limit the company's ability to diversify its sourcing options in response to supply chain disruptions. Additionally, the reliance on specific shipping routes and regulatory compliance of these suppliers are critical factors influencing the resilience of Cardinal 3PL's supply chain. Any disruptions in these areas could affect the company's ability to maintain a consistent supply of pharmaceutical products to the U.S. market.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for the safety, efficacy, and quality of drugs imported into the U.S. Pharmaceutical imports must comply with FDA standards, including proper labeling, manufacturing practices, and approval processes. For Indian pharmaceutical exporters, understanding and adhering to FDA regulations is essential for ensuring that their products are admissible into the U.S. market. This includes compliance with FDA's import procedures, which involve documentation, inspections, and potential sampling to verify product quality and safety.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Indian pharmaceutical exporters must ensure that their products are manufactured in facilities that comply with Good Manufacturing Practices (GMP) as recognized by the FDA. While the FDA does not have a formal mutual recognition agreement with India regarding GMP inspections, Indian manufacturers can seek FDA approval for their facilities. This process involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for each product intended for export to the U.S., demonstrating compliance with FDA standards. Additionally, Indian exporters must obtain a Drug Establishment Registration and Drug Listing Number from the FDA, which are necessary for the importation process.

Cardinal 3PL — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cardinal 3PL's product strategy focuses on importing finished pharmaceutical formulations in the therapeutic areas of antihistamines and cardiovascular medications. This focus aligns with market demand for these products in the United States, addressing the needs of patients requiring treatments for allergies and cardiovascular conditions. By concentrating on these specific therapeutic areas, Cardinal 3PL can streamline its sourcing and distribution processes, ensuring a consistent supply of essential medications to the U.S. market.

2Sourcing Profile

Cardinal 3PL's sourcing strategy emphasizes the importation of generic pharmaceutical formulations from India, particularly in the categories of antihistamines and cardiovascular drugs. This approach allows the company to offer cost-effective alternatives to brand-name medications, catering to the significant demand for generics in the U.S. market. India's established pharmaceutical manufacturing sector, with its adherence to international quality standards, makes it a reliable source for these products. By focusing on specific formulations and therapeutic areas, Cardinal 3PL can effectively meet market needs while maintaining supply chain efficiency.

3Market Positioning

Seller's Guide — How to Become a Supplier to Cardinal 3PL

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Cardinal 3PL, particularly those offering generic formulations in the therapeutic areas of antihistamines and cardiovascular medications. To capitalize on this opportunity, Indian exporters should ensure compliance with FDA regulations, maintain high-quality manufacturing standards, and establish reliable supply chain capabilities. By aligning their offerings with Cardinal 3PL's product focus and quality requirements, Indian suppliers can position themselves as valuable partners in meeting the U.S. market's demand for these essential medications.

2Requirements & Qualifications

Indian pharmaceutical exporters seeking to supply products to Cardinal 3PL and the U.S. market must obtain Drug Establishment Registration and Drug Listing Numbers from the FDA. Additionally, they must ensure that their manufacturing facilities comply with FDA's Good Manufacturing Practices (GMP) standards. Products must meet FDA's quality and labeling requirements, including accurate and truthful

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Cardinal 3PL

What products does Cardinal 3PL import from India?

Cardinal 3PL imports 2 pharmaceutical products across 2 categories. Top imports: Diphenhydramine ($1.9M), Verapamil ($650.0K).

Who supplies pharmaceuticals to Cardinal 3PL from India?

Cardinal 3PL sources from 3 verified Indian suppliers. The primary supplier is Micro Labs Limited (68.9% of imports, $5.1M).

What is Cardinal 3PL's total pharmaceutical import value?

Cardinal 3PL's total pharmaceutical import value from India is $2.5M, based on 51 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cardinal 3PL focus on?

Cardinal 3PL imports across 2 categories. The largest: Antihistamines & Allergy (74.5%), Cardiovascular (25.5%).

Get Full Cardinal 3PL Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.